Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: J Immunol. 2014 Sep 22;193(9):4303–4311. doi: 10.4049/jimmunol.1401505

Figure 2.

Figure 2

Bcl-3 is required for efficient DC-mediated cross-priming in vitro and in vivo. (A) WT and Bcl3−/− BMDCs were stimulated with LPS (100ng/ml) o.n., pulsed with OVA (100 μg/ml) for 3h, and co-cultured with CFSE-labeled OT-I T cells for 72h. T cells were analyzed by flow cytometry after staining and gating for CD8. Representative FACS plots and proliferation and division indices (FloJo) are shown. Mean ± SEM; n=5/group. (B) WT and Bcl3−/− BMDCs were treated as in (A) and IL-2 production in supernatants was analyzed with CBA. Mean ± SEM; n=5/group. (C) 5×106 CFSE-labeled CD45.1 OTI T cells were injected i.v. into CD45.2 WT and Bcl3−/− mice. 24h later animals were injected i.d. with OVA (1μg). Cells were isolated from spleens and draining lymphnodes 72h later, stained and gated for CD45.1 and CD8 and analyzed by flow cytometry. Data shown as in (A), with n=10 mice/group based on 2 experiments. *P<0.05, **P<0.01.